Skip to content

A study for expression profiles of blood nucleic acid in patients with cerebral damage

A study for expression profiles of blood nucleic acid in patients with cerebral damage

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015627
Enrollment
Unknown
Registered
2018-04-12
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral injury

Interventions

6 groups:none

Sponsors

China Rehabilitation Research Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Experimental group object selection: (1) adult patients with acquired brain injury. The experimental group (50): no craniocerebral trauma, the central or peripheral nervous system diseases, major organ failure, severe infection and malignant tumors, kidney diseases. Acute ischemic symptoms 0 to 7 d blood preservation. Recovery ischemic symptoms blood save 1 to 3 months; Control group: 50 healthy people: no craniocerebral trauma, the central or peripheral nervous system diseases, major organ failure, severe infection and malignant tumors, kidney diseases, matching with the control of gender, race, age > 40 years old, have no history of stroke. (2) patients with abnormal development of children's nervous system. The experimental group: Children with cerebral palsy(25): no craniocerebral trauma, the central or peripheral nervous system diseases, major organ failure, severe infections, malignant tumor, liver and kidney disease, genetic metabolic disease, epilepsy. There is a clear risk factors at birth, such as premature labor, asphyxia, jaundice. And their DQ more than 70. Note: according to the diagnosis of cerebral palsy in 2016 edition of cerebral palsy, the severity of the disorder was assessed according to the GMFM score standard. Children with autism(25): no craniocerebral trauma, the central or peripheral nervous system diseases, major organ failure, severe infections, malignant tumor, liver and kidney disease, genetic metabolic disease, epilepsy, unincorporated body movement disorders. Note: according to the icd-10 standard, diagnosis is autism, and the severity of the evaluation of CARS and PEP is evaluated. Control group(25): normal children.Inclusion criteria: without craniocerebral trauma, central or peripheral nervous system disease, major organ failure, severe infection, malignant tumor, liver and kidney disease, hereditary metabolic disease, epilepsy.

Exclusion criteria

Exclusion criteria: (1) adult patients with acquired brain injury. Incomplete medical records. Diagnosis is not clear or not recognized (all cases should be diagnosed by another neurologist with a blind method, and if there is no consensus, no agreement can be reached). The bleeding time exceeds 24 hours after the onset of ischemic related neurological symptoms. The final diagnosis was hemorrhagic stroke. (2) children patients with abnormal development of nervous system. Incomplete medical records: Diagnosis is not clear or not recognized (all cases must be diagnosed by another neurologist with a blind method, and if there is no consensus, no consensus can be reached).

Design outcomes

Primary

MeasureTime frame
MMSE;NIHSS;Developmental quotient;GMFCS;lncRNA;

Countries

China

Contacts

Public ContactZhang Tong

China Rehabilitation Research Center

tom611@126.com+86 13701395491

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026